Chiva Nabs Chinese Rights to Ligand's Hep B and HCC Candidates

StephenW

http://www.genengnews.com/gen-news-highlights/chiva-nabs-chinese-rights-to-ligand-s-hep-b-and-hcc-candidates/81244479/
    Chiva Nabs Chinese Rights to Ligand's Hep B and HCC Candidates   
   

        (Page        1        of        1)

                                            Chiva Pharmaceuticals negotiated Chinese development rights to Ligand Pharmaceuticals’ clinical-stage HepDirect candidates, Pradefovir for hepatitis B (hepB) and MB01733 for hepatocellular carcinoma (HCC). The deal also gives Chiva a nonexclusive license to use Ligand’s HepDirect technology for the discovery, development, and worldwide commercialization of new candidates against hep B, hep C, and HCC.
Ligand acquired Pradefovir, MB07133, and the HepDirect technology when it took over Metabasis in January 2010. Under terms of its new deal with Chiva, Ligand will receive $1 million in license payments during 2011, and could earn over $100 million in milestones and royalties on future sales, plus potentially a 10% equity stake in California-based Chiva, which is an affiliate of Hainan Kaihua Pharmaceutical.
“This strategic partnership with Chiva is a major event as it creates our first significant opportunity to introduce Ligand’s products and drug discovery capability in China,” remarks John L. Higgins, president and CEO at Ligand. “Less than a year ago, we brought into Ligand a basket of assets through our acquisition of Metabasis, and now this deal validates our ability to leverage our acquisitions and business platform to generate new deals.”
HepDirect is a prodrug technology that targets the delivery of drugs to the liver using a chemical modification that also renders the compound biologically inactive until cleaved by a liver-specific enzyme. Pradefovir is a HepDirect prodrug of PMEA, the active metabolite in the FDA-approved HepB drug adefovir dipivoxil (Hepsera®). The drug is currently in Phase II development in the U.S. MB07133 is a HepDirect prodrug of the intermediate form of cytarabine (araC) 5’-monophosphate. Currently in Phase I/II development treatment of hepatocellular carcinoma, the drug has already demonstrated strong response rates in terms of intrahepatic tumor regression in a U.S. trial, Ligand states.  
奇瓦哥们中权利配体的乙肝和肝癌的考生

   
（页1）

      奇瓦制药谈判到配体制药公司的临床阶段，HepDirect候选人中发展权Pradefovir乙型肝炎（乙肝）和肝细胞癌（HCC）的MB01733。这笔交易还使奇瓦非独占许可使用的发现，开发配体的HepDirect技术，以及对乙肝，丙肝和肝癌的新的候选人的全球商业化。

      配体收购Pradefovir，MB07133和HepDirect技术当它在2010年1月Metabasis了。根据其与奇瓦新的交易条件，配体将获得在2011美元的许可费100万，并能赚取超过1亿美元的里程碑和版税未来的销售，加上可能在加利福尼亚州的奇瓦，10％的股权是一海南制药子公司开化。

      “这与奇瓦战略伙伴关系是一个重大的事件，因为它创建了我们的第一个重要的机会，介绍中国配体的产品和药物发现能力”的言论约翰L希金斯，总裁和首席执行官配体。 “不到一年前，我们通过我们带进配体的Metabasis收购一篮子资产，现在这笔交易证明了我们能够利用我们的收购和业务平台，以产生新的交易。”

      HepDirect是一种药技术为目标的药物运送到肝脏中的一种化学修饰，也呈现复合生物无效，直至被肝脏特异性酶切割。 Pradefovir是阿德福韦HepDirect药，在美国FDA批准的乙肝药物阿德福韦酯的活性代谢物（Hepsera ®）。该药物是在第二阶段，在美国MB07133发展，目前是一个中间形式的阿糖胞苷（阿糖胞苷）5' -磷酸HepDirect药。目前在第I / II治疗肝癌的发展，已经证明这种药物在肝内肿瘤缩小条款在美国审判，配体国家的强烈反应率。
        

(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc